AI assistant
GlaxoSmithKline PLC Director's Dealing 2024
5262_dirs_2024-10-14_7d9db780-4a3b-4e46-9f17-f5ecec55c8ae.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 1003I
GSK PLC
14 October 2024
GSK plc (the ' Company ')
Transaction notification
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Elizabeth McKee Anderson | |||
| b) | Position/status | Independent Non-Executive Director | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044 |
|||
| b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 10 October 2024 | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| $39.0587 | 16 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2024-10-11 | |||
| f) | Place of the transaction | New York Stock Exchange (XNYS) |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Charles Bancroft | |||
| b) | Position/status | Senior Independent Non-Executive Director | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044 |
|||
| b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 10 October 2024 | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| $39.0587 | 105 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2024-10-11 | |||
| f) | Place of the transaction | New York Stock Exchange (XNYS) |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Dr Hal Barron | |||
| b) | Position/status | Non-Executive Director | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044 |
|||
| b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 10 October 2024 | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| $39.0587 | 19 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2024-10-11 | |||
| f) | Place of the transaction | New York Stock Exchange (XNYS) |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Dr Anne Beal | |||
| b) | Position/status | Independent Non-Executive Director | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044 |
|||
| b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 10 October 2024 | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| $39.0587 | 14 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2024-10-11 | |||
| f) | Place of the transaction | New York Stock Exchange (XNYS) |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Dr Harry Dietz | |||
| b) | Position/status | Independent Non-Executive Director | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044 |
|||
| b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 10 October 2024 | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| $39.0587 | 14 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2024-10-11 | |||
| f) | Place of the transaction | New York Stock Exchange (XNYS) |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Dr Jesse Goodman | |||
| b) | Position/status | Independent Non-Executive Director | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044 |
|||
| b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 10 October 2024 | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| $39.0587 | 14 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2024-10-11 | |||
| f) | Place of the transaction | New York Stock Exchange (XNYS) |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Dr Jeannie Lee | |||
| b) | Position/status | Independent Non-Executive Director | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044 |
|||
| b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 10 October 2024 | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| $39.0587 | 2 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2024-10-11 | |||
| f) | Place of the transaction | New York Stock Exchange (XNYS) |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Dr Vishal Sikka | |||
| b) | Position/status | Independent Non-Executive Director | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044 |
|||
| b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 10 October 2024 | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| $39.0587 | 64 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2024-10-11 | |||
| f) | Place of the transaction | New York Stock Exchange (XNYS) |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHFFDFELELSESS